Elevated levels of serum CDCP1 in individuals recovering from severe COVID-19 disease.

Autor:	Blanco JR; Servicio de Enfermedades Infecciosas, Hospital Universitario San Pedro, Logroño, La Rioja, Spain.; Centro de Investigación Biomédica de La Rioja, Logroño, La Rioja, Spain., Cobos-Ceballos MJ; Instituto Maimónides de Investigación Biomédica de Córdoba, Universidad de Córdoba, Córdoba, Spain.; Servicio de Neumología, Hospital Universitario Reina Sofía, Córdoba, Spain., Navarro F; Servicio de Medicina Interna, Hospital Costal de Sol, Marbella, Málaga, Spain., Sanjoaquin I; Servicio de Enfermedades Infecciosas, HCU Lozano Blesa, Zaragoza, Spain., Armiñanzas C; Servicio de Enfermedades Infecciosas, H Universitario Marqués de Valdecilla, Santander, Spain., Bernal E; Unidad de Enfermedades Infecciosas, Hospital General Universitario Reina Sofía de Murcia, Murcia, Spain., Buzon-Martin L; Servicio de Medicina Interna, Hospital Universitario de Burgos, Burgos, Spain., Viribay M; Vitro Laboratory, Madrid, Spain., Pérez-Martínez L; Centro de Investigación Biomédica de La Rioja, Logroño, La Rioja, Spain., Espejo-Pérez S; Instituto Maimónides de Investigación Biomédica de Córdoba, Universidad de Córdoba, Córdoba, Spain.; Servicio de Radiología, Hospital Universitario Reina Sofía, Córdoba, Spain., Valencia B; Servicio de Neumología, Hospital Costal de Sol, Marbella, Málaga, Spain., Guzman-Aguilar J; Servicio de Neumología, HCU Lozano Blesa, Zaragoza, Spain., Ruiz-Cubillan JJ; Servicio de Neumología, H Universitario Marqués de Valdecilla, Santander, Spain., Alcalde C; Servicio de Neumología, Hospital General Universitario Reina Sofía de Murcia, Murcia, Spain., Gutierrez-Herrero FG; Servicio de Neumología, Hospital Universitario de Burgos, Burgos, Spain., Olalla J; Servicio de Medicina Interna, Hospital Costal de Sol, Marbella, Málaga, Spain., Andres-Esteban EM; Grupo PBM, Instituto de Investigación-IdiPaz, Madrid, Madrid, Spain.; Universidad Rey Juan Carlos, Madrid, Madrid, Spain., Jurado-Gamez B; Instituto Maimónides de Investigación Biomédica de Córdoba, Universidad de Córdoba, Córdoba, Spain.; Servicio de Neumología, Hospital Universitario Reina Sofía, Córdoba, Spain., Ugedo J; Servicio de Neumología, Hospital Universitario San Pedro, Logroño, La Rioja, Spain.
Jazyk:	angličtina
Zdroj:	Aging [Aging (Albany NY)] 2022 Feb 16; Vol. 14 (4), pp. 1597-1610. Date of Electronic Publication: 2022 Feb 16.
DOI:	10.18632/aging.203898
Abstrakt:	Background: COVID-19 survivors report residual lung abnormalities after discharge from the hospital. The aim of this study was to identify biomarkers in serum and induced sputum samples from patients after hospitalization for COVID-19. Methods: Patients admitted to hospitals in Spain with laboratory-confirmed COVID-19 were recruited for this study. SARS-CoV-2-infected patients were divided into groups with mild/moderate and severe disease according to the severity of their symptoms during hospitalization. Levels of 92 biomarkers were measured in serum and induced sputum samples. Results: A total of 108 patients (46.2% severe cases) were included in this study. The median number of days after the onset of symptoms was 104. A significant difference was observed in diffusing capacity for carbon monoxide (DLCO), an indicator of lung function, whereby DLCO <80% was significantly lower in severe cases (p <0.001). Differences in inflammatory biomarkers were observed between patients with mild/moderate and severe disease. For some biomarkers, correlations in serum and induced sputum levels were detected. Independent predictors of severe disease were DLCO <80% and the serum CDCP1 value. Conclusions: Higher levels of CDCP1 remain after hospital discharge and are associated with the severity of COVID-19. The possible prognostic implications warrant further investigation.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu